These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 2313850)

  • 21. [Adverse drug reactions following immunization in Germany pursuant to the German Infection Protection Act and the German Medicinal Products Act from January 1, 2004 to December 31, 2005].
    Weisser K; Meyer C; Petzold D; Mentzer D; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Nov; 50(11):1404-17. PubMed ID: 17999134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
    Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse drug events and near misses: who's counting?
    Wu AW
    Am J Med; 2000 Aug; 109(2):166-8. PubMed ID: 10967161
    [No Abstract]   [Full Text] [Related]  

  • 24. Silicone gel breast implant adverse event reports to the Food and Drug Administration, 1984-1995.
    Brown SL; Parmentier CM; Woo EK; Vishnuvajjala RL; Headrick ML
    Public Health Rep; 1998; 113(6):535-43. PubMed ID: 9847926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of postmarketing surveillance in contemporary medicine.
    Woodcock J; Behrman RE; Dal Pan GJ
    Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse drug reaction processing in the United States and its dependence on physician reporting: zomepirac (Zomax) as a case in point.
    Corre KA; Spielberg TE
    Ann Emerg Med; 1988 Feb; 17(2):145-9. PubMed ID: 3257365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. National adverse drug reaction surveillance. 1986.
    Faich GA; Dreis M; Tomita D
    Arch Intern Med; 1988 Apr; 148(4):785-7. PubMed ID: 3355297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Miscategorization of Deaths in the US Food and Drug Administration Adverse Events Database.
    Meier L; Wang EY; Tomes M; Redberg RF
    JAMA Intern Med; 2020 Jan; 180(1):147-148. PubMed ID: 31589249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reporting of adverse events to MedWatch.
    Piazza-Hepp TD; Kennedy DL
    Am J Health Syst Pharm; 1995 Jul; 52(13):1436-9. PubMed ID: 7671043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse reactions reported following receipt of Haemophilus influenzae type b vaccine: an analysis after 1 year of marketing.
    Milstien JB; Gross TP; Kuritsky JN
    Pediatrics; 1987 Aug; 80(2):270-4. PubMed ID: 3497381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mammography referral patterns among Rhode Island physicians.
    Feldman JP; Donnelly EF; Fulton JP; Smith RA; DeBuono BA; Scott HD
    R I Med J (1976); 1990 Dec; 73(12):591-7. PubMed ID: 2293312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA turns to electronic "sentinel" to flag prescription drug safety problems.
    Kuehn BM
    JAMA; 2008 Jul; 300(2):156-7. PubMed ID: 18612108
    [No Abstract]   [Full Text] [Related]  

  • 33. US Food and Drug Administration: adverse event reporting.
    Graham AA
    CRNA; 1998 Nov; 9(4):135-8. PubMed ID: 9866488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors that influence spontaneous reporting of adverse drug reactions: a model centralized in the medical professional.
    Herdeiro MT; Polonia J; Gestal-Otero JJ; Figueiras A
    J Eval Clin Pract; 2004 Nov; 10(4):483-9. PubMed ID: 15482410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reported adverse drug events in infants and children under 2 years of age.
    Moore TJ; Weiss SR; Kaplan S; Blaisdell CJ
    Pediatrics; 2002 Nov; 110(5):e53. PubMed ID: 12415059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse behavioral reactions attributed to triazolam in the Food and Drug Administration's Spontaneous Reporting System.
    Wysowski DK; Barash D
    Arch Intern Med; 1991 Oct; 151(10):2003-8. PubMed ID: 1929688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recognizing, reporting, and reducing adverse drug reactions.
    Brown SD; Landry FJ
    South Med J; 2001 Apr; 94(4):370-3. PubMed ID: 11332899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
    Stobaugh DJ; Deepak P; Ehrenpreis ED
    J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in monitoring of adverse drug reactions in Poland.
    Czarnecki A; Maciejczyk A
    Acta Pol Pharm; 1998; 55(4):319-21. PubMed ID: 9821398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.